| | | BP controlled group | BP uncontrolled group | P value | | (n=66) | (n=54) |
| | Age (yr) | 57.03±6.81 | 59.30±8.26 | 0.109 | | Male gender (n, %) | 27/66 (40.9%) | 27/54 (50.0%) | 0.319 | | BMI (kg/m2) | 25.19±3.34 | 25.22±3.25 | 0.954 | | Smoker (n, %) | 20/66 (30.3%) | 20/54 (37.0%) | 0.436 | | Stable CAD (n, %) | 18/66 (27.3%) | 19/54 (35.1%) | 0.350 | | Dyslipidemia (n, %) | 58/66 (87.9%) | 47/54 (87.0%) | 0.890 | | SBP (mmHg) | 124.97±9.72 | 147.20±10.45 | <0.0001 | | DBP (mmHg) | 78.02±7.43 | 86.82±10.97 | 0.000 | | Heart rate (bpm) | 72.35±8.27 | 74.03±8.00 | 0.364 | | Creatinine (μM) | 67.14±14.87 | 67.59±14.46 | 0.867 | | CHOL (mM) | 4.83±0.93 | 4.84±1.08 | 0.945 | | TG (mM) | 2.00±1.49 | 2.29±2.68 | 0.663 | | LDL-c (mM) | 2.97±0.81 | 2.86±0.84 | 0.472 | | HDL-c (mM) | 1.11±0.25 | 1.09±0.30 | 0.436 | | Ejection fraction (%) | 62.33±4.78 | 61.39±5.60 | 0.321 | | LVEDd (cm) | 4.40±0.48 | 4.41±0.39 | 0.907 | | IVS (cm) | 1.00±0.15 | 1.00±0.22 | 0.891 | | Medication | | | | | Bata-blockers (n, %) | 32/66 (48.5%) | 28/54 (51.9%) | 0.714 | | ACEI (n, %) | 14/66 (21.2%) | 12/54 (22.2%) | 0.894 | | ARBs (n, %) | 19/66 (28.8%) | 23/54 (42.6%) | 0.115 | | CCB (n, %) | 37/66 (56.1%) | 39/54 (72.2%) | 0.068 | | Diuretics (n, %) | 6/66 (9.1%) | 6/54 (11.1%) | 0.714 | | Categories of drugs | | | 0.021 | | Monotherapy (n,%) | 32/66 (48.5%) | 15/54 (27.7%) | | | ≥Two-drug therapy (n, %) | 34/66 (51.5%) | 39/54 (72.2%) | |
|
|
BP, blood pressure; BMI, body mass index; CAD, coronary artery disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; CHOL, cholesterol; TG, triglyceride; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol; LVEDd, left ventricular end diastolic diameter; IVS, interventricular septum; ACEI, angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blocker; CCB, calcium channel blocker.
|
